Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.
about
Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failureDiabetic cardiomyopathy: bench to bedsideCongestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvementGLP-1 and cardioprotection: from bench to bedsideAlbiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiencyA protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.Diabetes and cardiovascular disease: the potential benefit of incretin-based therapiesAssociation of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes.Glucose metabolism and cardiac hypertrophySelective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesExendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrixDesign and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover studyAsymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitusCardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat HeartA meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure.GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway.Investigation of the haemodynamic effects of exenatide in healthy male subjects.The cardiovascular effects of GLP-1 receptor agonists.Cardiovascular biology of the incretin system.Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism.Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium.Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling.Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway.Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection.Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitusIncretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptidesDipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.Pathological ventricular remodeling: therapies: part 2 of 2.Inducible overexpression of GLUT1 prevents mitochondrial dysfunction and attenuates structural remodeling in pressure overload but does not prevent left ventricular dysfunction.Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?Cardiac metabolism in heart failure: implications beyond ATP production.Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.Merits of non-invasive rat models of left ventricular heart failure.Effects of incretins on blood pressure: a promising therapy for type 2 diabetes mellitus with hypertension.
P2860
Q26829634-E3D43E44-C36D-49DA-9B81-564BEF9AFEF3Q26997062-98751F22-2839-4780-9BF2-0ECF9B20FF7FQ27003819-CFF0314D-105D-4DE9-85F7-BF04376B7A9EQ27024984-05182833-E80A-45FD-A4FE-81A7D7260FCFQ28740948-77510733-101D-4A30-A8C5-83E92216245EQ30437335-1E403050-99AB-4B8A-A9C7-60C40826497FQ33603384-75BE1362-247C-4EC5-BA0B-35ECE7334573Q33832036-4C1FB643-5139-4B43-A2E8-2F1ADB239B4DQ34716791-34A7AA2F-F5DA-432C-85ED-5E6D603FAFF0Q34771795-905CF883-6195-4618-ABED-D33649EF292DQ34808553-605FB72A-33C7-49E1-A06E-40AFC1BE1394Q34994502-B6DC5CC3-2D80-4853-AA7F-5BDA346C69C1Q35132702-7F04CE95-D1A0-4058-9E93-0B3FF3F28602Q35174285-9102B370-5CE3-4A3F-B11E-7E272961AB5CQ35622245-7ED6D37A-6370-4C64-A8E2-5CDE5588EFA8Q35670896-76A048A2-8DE4-45A6-BE70-9041E39C81FCQ36090588-07A6CAA6-328D-40C7-A28A-A6779CADCB14Q36209853-76378995-01B8-4DB6-BCAA-EA929B962BC2Q36336020-3384E9CA-349B-4DEB-BEC3-B4D14509A0B3Q36368998-A38D38C0-3BF6-439F-994E-A6887745E260Q36484283-DC908934-EF7A-4856-AF3A-2EBE3272BCB2Q36689230-731C2683-D512-4558-BCC6-03BF058F0C80Q36721264-03A8498C-B606-4D27-8E25-30DB44808230Q36800422-856B83AE-45B3-46F5-84B8-50133FDD7083Q36825702-8609A989-84EC-4398-B04E-5FDDE3AA99A3Q36965895-CEB50071-BAC0-424C-8207-3F781FEB36FAQ36980756-65493257-B378-4996-B594-F90211ABB65EQ37065219-BD9E56C3-CFD1-4C91-AA5A-AFF2C85B5D58Q37082698-F375E2C8-E277-484D-8A64-A49B97837DA6Q37212333-19E94CD4-9897-4588-8141-A4D69342E556Q37274296-93AC9DC6-BD19-4462-8BD8-053543B4911DQ37312758-9EA3EA42-B9F5-47BB-97B2-A6F54CB1D747Q37328748-37BA11F5-3F20-41AA-A794-A2A2C58E3877Q37395298-37356EDD-26D1-49EA-95E6-1AD4DEBCCAF7Q37495811-746F6138-202A-4570-B1E7-D3E8CE34F4AAQ37597536-3DB9BC5E-F0E9-4B20-AFC0-441078A1DED9Q37704721-64754CC8-50E1-44CA-B9DA-45CC5B36FC81Q37825946-CFD37A51-B818-4FDF-8BEF-BF51650E090AQ37833553-AEE470DA-0A29-4197-B83A-4DEC6E5D02BCQ37951097-40D5B31E-C895-45FB-A5DB-B1BA5C18A12D
P2860
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chronic glucagon-like peptide- ...... sive, heart failure-prone rat.
@en
Chronic glucagon-like peptide- ...... sive, heart failure-prone rat.
@nl
type
label
Chronic glucagon-like peptide- ...... sive, heart failure-prone rat.
@en
Chronic glucagon-like peptide- ...... sive, heart failure-prone rat.
@nl
prefLabel
Chronic glucagon-like peptide- ...... sive, heart failure-prone rat.
@en
Chronic glucagon-like peptide- ...... sive, heart failure-prone rat.
@nl
P2093
P2860
P1476
Chronic glucagon-like peptide- ...... sive, heart failure-prone rat.
@en
P2093
Hakki Bolukoglu
Indu Poornima
Pratik Parikh
Richard P Shannon
Siva Bhashyam
Suzanne B Brown
P2860
P304
P356
10.1161/CIRCHEARTFAILURE.108.766402
P577
2008-09-01T00:00:00Z